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ABSTRACT 
Therefore, there is a need to develop alternative novel drug delivery formulations of albendazole to improve its intestinal absorption and also to 
reduce its side effects during regular therapy. The Albendazole nanoparticles were prepared by hot homogenization method under high 
magnetic stirring using stearic acid as lipid and poloxamer 188 was used as surfactant. Initial pre-formulation studies using FTIR spectroscopy 
reveals that there are no interactions between Albendazole and other excipients and hence they can be used for the preparation of nanoparticles. 
The entrapment efficiencies varied from a minimum of 43.56 ± 0.95 % to a maximum of 85.1 ±0.58% and it can be concluded that higher amount 
of lipid is necessary for obtaining a good entrapment efficiency. The drug content of albendazole nanoparticles for all formulation ranges from 
65.8% to 98.1%. A spherical shape was observed for the particles and the particles had a smooth morphology when examined under SEM. In 
vitro release studies of the formulations carried out in pH 7.4 PBS showed that the total amount of drug is released for 9hrs with sustained effect. 
That the formulations showed a drastic increase in size when stored at room temperature where the size of particles increased from an initial to 
343.7 ±7.9 nm at the end of 1 month to 898.1 ± 5.8 nm at the end of 2 months. Entrapment efficiency of the formulation was determined at each 
interval to ensure that the drug molecules didn’t undergo any degradation during storage. 
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INTRODUCTION 
Nanoparticles consist of a solid lipid matrix (at room and 
body temperatures) which are stabilized by surfactants and 
have a mean size of 50- 1000 nm and stabilized by 
surfactants 1. The main advantages of Nanoparticles are a 
controlled release of the drug can be achieved, The stability 
of the drug can be improved, high amounts of drug loading 
can be achieved, hydrophilic and lipophilic drugs can be 
incorporated there is no toxicity of the various lipids used of 
organic solvents can be prevented, Preparation of large scale 
of Nanoparticles can be easily scaled up for industrial 
purpose 2. Nanoparticle are solid colloidal particles ranging 
from 10 to 1000 nm (1.0 μm), in which the active principles 
(drug or biologically active material) are dissolved, 
entrapped, and/or to which the active principle is adsorbed 
or attached 3. In recent years, significant effort has been 
devoted to develop nanotechnology for drug delivery, since 
it offers a suitable means of delivering small molecular 
weight drugs, as well as macromolecules such as proteins, 
peptides or genes to cells and tissues and prevents them 
against enzymatic degradation 4. Therefore, there is a need 
to develop alternative novel drug delivery formulations of 
albendazole to improve its intestinal absorption and also to 
reduce its side effects during regular therapy. Already, 
approaches like albendazole suspensions, liposome’s and 
polymeric nanoparticles were developed to improve the 
efficacy 5.  
MATERIALS & METHODS 
The Albendazole was purchased from Chimak Health Care, 
Himachal Pradesh, Excipients like Steric acid, Polaxamer 118 
was procured from Sigma Aldrich chemicals Pvt. Ltd., USA, 
Bees wax, Dimethyl formamide, Sodium hydroxide, was 
procured from S.D. Fine Chem. Ltd. Mumbai. All other 
reagents used were of analytical grade. 
Methodology: 
FT-IR Studies: The purity of the drug was determined by 
subjecting Albendazole for IR analysis using Fourier 
Transform Infrared Spectroscopy (FT/IR 8400S (CE) 
Shimadzu spectrophotometer). The samples were prepared 
as KBr pellet method. Drug and potassium bromide are 
mixed in the ratio of 1:100 and a pellet is formed by 
compressing at 8 ton/mm2 pressure 6. The wavelength range 
was selected from 400 - 2000 cm-1 in Shimadzu FT-IR 
spectrophotometer. Similarly an IR peak is obtained for 
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physical mixture of Albendazole, Stearic acid, Bees wax, 
Polaxamer 188 and mixtures. 
Formulation Development of Albendazole 
Nanoparticles: The Nanoparticles of Albendazole were 
prepared by hot homogenization method under high speed 
magnetic stirring with slight modifications. An accurately 
weighed quantity of lipid & wax was heated carefully on a 
water bath at 80 °C in order to form a melted phase of the 
lipid & Wax. To this melted lipid Albendazole was added and 
was heated until a clear homogeneous phase is formed 7. 
Simultaneously, a weighed quantity of the surfactant was 
added to the water to form an aqueous phase which is also 
heated to 80°C. The hot lipid phase was dispersed in the 
surfactant solution and stirred on magnetic stirrer for 30 
minutes continuously to form solid lipid nanoparticles of 
Albendazole.
  
Table 1 Composition of Albendazole Nanoparticles formulations 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Albendazole (mg) 20 20 20 20 20 20 20 20 
Stearic acid (mg)  150 150 100 100 150 150 110 110 
Bees Wax (mg) 100 100 120 120 150 150 130 130 
Polaxamer (mg)  200 200 200 200 200 200 200 200 
Span 80 (ml) 0.5 0.75 1.0 1.25 0.5 0.75 1.0 1.25 
Ethanol (ml) 10 10 101 10 10 10 10 10 
 
Scanning Electron Microscopy: The prepared Nanoparticle 
formulation was examined for surface morphology and 
shape using scanning electron microscope 8. The scanning 
electron microscopy was performed on Hitachi high 
technologies corporation-S4800 type II, Japan. The samples 
were dried thoroughly in vacuum desiccators before 
mounting on brass specimen studies.  
Particle Size: The average mean diameters and size 
distribution of albendazole loaded nanoparticles was found 
out by photon correlation spectroscopy using a Zeta sizer 
(nano ZS90, Malvern Instruments) at 25°C. The samples 
were kept in polystyrene cuvette and the readings were 
noted at a 90° fixed angle 9. 
Zeta Potential: The electrophoretic mobility (zeta potential) 
measurements of drug loaded nanoparticles were made 
using Zeta sizer (Nano ZS90, Malvern Instruments). The 
samples were placed in a polystyrene cuvette (at 25°C) and a 
Zeta dip cell was used to find out the potential 10.  
Entrapment Efficiency: 2ml of the formulation was taken 
and ultra-centrifuged at 13, 000 rpm at 4°C for 90 minutes 
using Eppendrof centrifuge 11. The supernatant was 
recovered using micro pipette and analyzed by UV method 
for free drug content.   
Drug content:  50mg of Albendazole nanoparticles was 
crushed and suspended in water to extract the drug from the 
nanoparticles. After 24 h, the filtrate was assayed 
spectrophotometrically at 295 nm for drug content against 
water as blank 12. 
In Vitro Release Studies: The in vitro release studies was 
carried out using in pH 7.4 phosphate buffer by dialysis bag 
method with a molecular weight cut off of 12,000- 14,000 Da. 
Precisely 2 ml of the formulation was placed in the dialysis 
bag by sealing both the ends with the help of clips. The 
dialysis bag is dipped in a 50 ml dissolution medium 
maintained at 37± °C and stirred at 100 rpm using a 
magnetic stirrer. 2 ml of the buffer solution is removed at an 
interval of 1, 2, 3, 4, 6, 7, 8 and 10 hrs and is replaced by an 
equal amount of fresh buffer to maintain sink conditions 13. 
The content of drug in the samples was determined by ultra-
visible spectroscopy at λmax of 295 nm. 
Stability Studies as per ICH guidelines: Stability of 
formulations during storage includes the preservation of 
initial particle size and prevention of degradation reactions.  
Stability studies were carried out for freeze dried method.  
The samples were stored in room temperature (25 to 30 °C) 
and in refrigerator (3 to 5 °C) over a period of 2 months. 
Samples were evaluated at 0, 1 and 2 months for their 
particle size, entrapment efficiency and changes in their 
physical appearance 14. 
 
 
RESULTS AND DISCUSSION 
Drug excipients compatibility studies 
 
Figure 1: FT IR Spectra of Albendazole 
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Figure 2: FTIR spectra of Stearic acid 
 
Figure 3: FTIR spectra of Bees wax 
 
 
Figure 4: FTIR spectra of Poloxamer 188 
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Figure 5: FTIR spectra of drug and polymer mixture 
 
Table 2: FTIR Interpretation drug and polymer mixture 
Albendazole 
S. No. 
 
 Interpretation IR absorption bands (cm-1) 
 Characteristic peak Observed peak 
1. C–Cl stretch 850–550 742.87 
2. C–N stretch 1250–1020 1069.93 
3. C–N stretch 1250–1020 1247.59 
4. C=O stretch 1740–1720 1731.94 
5. O–H stretch 3500–3200 3463.35 
Stearic acid 
1. C-H Bend 1650-1580 1644 
2. C-C Stretch 1600-1585 1546 
3. C-H Stretch 3000-2850 2955, 2895 
Bees Wax 
1. C-Br Stretch 690-515(m) 641.88 
2. O-H Bend 950-910(m) 633.87 
3. C-O Stretch 1320-1000(m) 1297.71 
4. C-H Bend 1470-1450(m) 1456.61 
Eudragit RS 100 
1. (s)= C-H bend 1000-650 745 
2. (s, b) N-H wag              900-675 754 
3. (s) C-O stretch 1320-1000 1056 
Poloxamer 188 
1. C–O stretch 1320–1000 1175 
2. C–H wag 1300–1150 1133 
3. C–C stretch  1500–1400 1423 
4. N–H bend 1650–1580 1602 
Drug + Polymer Mixture 
1. O-H stretch 3300-2500 3055,2955 
2 C-O Stretch 1320-1000 1128 
3 N-H Bend 1650-1580 1628 
4 N-O Stretch 1550-1475 1509 
 
Formulation of albendazole nanoparticles: They were 
prepared by hot homogenization method under high speed 
magnetic stirring using stearic acid as lipid, Bees wax act as a 
wax and poloxamer 188 as surfactant. On a whole 8 
formulations were prepared by changing the different ratios 
of lipids &Wax. The percentage of surfactant used ranging 
from 0.5, 0.75, 1.0 & 1.25%). 
Determination of particle shape and surface morphology 
by using scanning electron microscopy: Scanning electron 
microscopy image revealed that the particles have a smooth 
texture and a spherical morphology as shown in figure 6.
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Figure 6: Scanning Electron Microscope image of the Nanoparticles 
 
Determination of particle size by photon correlation 
spectroscopy: The Zeta average diameters of the 
formulations are mentioned in table 3. The values show that 
the size of the nanoparticles for all formulations ranges from 
110.6 ±1.5 nm to 400.9 ± 2.4nm. The effect of various 
concentrations of lipids and surfactants on the size of the 
particles was studied. 
Determination of zeta potential: The Zeta potential of all 
the formulations varied between -0.04 ±1.6mV and -9.15 
±1.1 mV and is mentioned in table 3. Poloxamer being a non-
ionic surfactant was not able to induce potential on the 
surface of the nanoparticles and the partial negative 
observed was due to the charge induced by lipid and and 
drug.                                                                
Determination of entrapment efficiency: The 
encapsulation efficiencies mentioned in table 3 reveals that 
the in all the formulations the drug is moderately 
encapsulated and the values varied between a minimum of 
43.56 ± 0.95 to 85.1 ± 0.58%.  Albendazole being a 
hydrophobic drug has shown moderate entrapment in the 
stearic acid 
Drug content: The Drug content mentioned in table 3 
reveals that the in all the formulations the drug is 
moderately encapsulated and the values varied between a 
minimum of 65.8 % to 98.1% for formulation. 
 
Table 3: Evaluations of Albendazole Nanoparticles 
Formulation 
code 
Zeta  Size 
(nm) 
Polydispersity 
index  
Zeta potential 
(mV) 
Entrapment 
Efficiency (%) 
Drug 
content %) 
ANF1 110 ± 1.5 0.215 ±0.23 -4.71  ±1.3 43.56  ±0.95 65.8 
ANF2  211 ±1.23 0.304±0.4 -1.16 ±1.7 54.61 ±1.2 69.2 
 ANF3 227 ± 2.3 0.355 ±0.12 -4.29 ±1.9 47.91 ±1.1 90.3 
ANF4 249 ± 0.59 0.215±1.4 -0.261 ±1.2 85.12 ±0.58 98.1 
 ANF5 332 ± 1.41 0.407 ±1.9 -9.15 ±1.1 45.72 ±0.69 75.2 
ANF6 367±0.99 0.521 ±1.3 -0.04 ±1.6 56.34 ±0.55 85.2 
 ANF7 400 ±2.4 0.02 ±1.1 -4.32 ±2.3 48.01 ±1.2 88.5 
ANF8 108 ±0.94 0.656 ±1.8 -7.83 ±0.98 64.9 ± 1.4 78.2 
 
In Vitro drug release studies: In this section, the in vitro 
drug release studies have been carried out in pH 7.4 buffer 
(simulated intestinal pH) using a Dialysis bag which allows 
only the drug released from the nanoparticles to pass across 
the membrane. The drug solution was taken in the Dialysis 
bag which is placed in the buffer and samples are withdrawn 
at regular intervals of time for measuring drug 
concentration. All the formulations release till 10hrs which 
extend the therapeutic activity in the disease site. The 
release has followed biphasic pattern where 30-40% of the 
drug was released in first 1 hr and the remaining got 
released till 9 hrs.  
 
Table 4: In vitro release release studies of albendazole nanoparticles 
Time 
(Hrs) 
                                         % of Drug release 
ANF1 ANF2 ANF3 ANF4 ANF5 ANF6 ANF7 ANF8 
1 Hrs 5.54 3.06 5.96 6.23 11.58 13.14 14.64 7.68 
2 Hrs 19.62 16.96 16.24 17.06 15.42 16.98 29.32 12.36 
3 Hrs 27.96 24.46 23.59 24.80 19.32 23.16 33.16 24.64 
4 Hrs 38.68 31.58 32.64 38.64 23.16 33.94 37.72 39.32 
5 Hrs 41.58 45.42 49.32 46.38 37.06 46.31 47.86 43.16 
6 Hrs 55.42 57.06 50.91 50.22 47.08 58.64 52.48 55.32 
7 Hrs 67.06 64.8 74.81 74.12 59.42 60.98 65.60 68.64 
8 Hrs 70.19 72.48 81.10 81.86 62.64 71.11 78.62 74.19 
9 Hrs 88.64 80.22 89.12 94.92 70.26 76.56 87.28 89.86 
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Figure 7: In Vitro Release Release Studies of Albendazole Nanoparticles 
Table 5: Release kinetics of Albendazole Nanoparticles ANF1 TO ANF5 
 
Table 6: Release kinetics of Albendazole Nanoparticles ANF6 TO ANF8 
Model ANF  6 ANF  7 ANF   8 
R2 M R2 m R2 M 
Zero order 0.917 15.49 0.949 154.4 0.937 1593 
First order  0.481 0.052 0.465 0.051 0.399 0.061 
Higuchi’s Matrix 0.798 1057 0.848 1067 0.899 11409 
Korsmeyer-Peppas 0.835 2.032 0.827 2.033 0.785 2.560 
 
Stability Studies: Smaller particles tend to aggregate faster 
during transport, storage and dispersion. Stability studies 
were carried out on freeze dried at room temperature (20 - 
25°C) and refrigerator (3 to 5 °C) over a period of 2 months. 
Particle size, appearance of the formulation, drug release and 
FT-IR were evaluated to confirm the stability of the 
formulation. When stored at room temperature, the 
formulations showed instability by formation of larger 
floccules and when dispersed in water the solution turned 
into heavier particles. Whereas, the formulation when stored 
in refrigerated condition was stable with no visible floccules 
formation. Hence, it is concluded that the formulations 
should be stored in refrigerated conditions. When stored at 
room temperature where the size of particles increased from 
an initial to 343.7 ±7.9 nm at the end of 1 month to 898.1 ± 
5.8 nm at the end of 2 months. The Entrapment Efficiency of 
formulation didn’t show any change during the 60 days of 
storage in both refrigerated condition and room 
temperature. The entrapment efficiency is mentioned in 
table 8 & 9. 
 
Table 8:  Particle sizes of the formulations during stability studies 
Stability Condition 
Average Particle size of DS15 (nm) 
0 days 1 month 2 months 
Room temperature (25°C) 249 ± 0.59 343.7 ±7.9 899.8  ± 5.8 
Refrigerated temperature (3 to 5 °C) 249 ± 0.59 255 ± 0.19 280 ± 0.39 
 
Table 9: Entrapment efficiency of formulation on storage condition 
Storage condition Day 30 Day 60 
Room temperature    73.1 ±0.58% 72.29 ±3.2% 
Refrigerated temperature  75.1 ±0.58% 76.53±3.6% 
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Model ANF  1 ANF   2 ANF   3 ANF  4 ANF  5 
R2 m R2 m R2 m R2 m R2 m 
Zero order 0.655 69.4 0.939 1123 0.007 15.93 0.202 72.88 0.928 1414 
First order  0.494 0.061 0.540 0.067 0.257 0.038 0.352 0.044 0.438 0.062 
Higuchi’s 
Matrix 
0.516 4508 0.767 7420 0.023 212.0 0.189 515.5 0.803 9618 
Korsmeyer-
Peppar 
0.835 2.354 0.884 2.545 0.572 1.709 0.663 1.813 0.806 2.517 
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SUMMARY & CONCLUSION 
The present work was proposed to prepare and optimize 
Albendazole loaded Nanoparticle to improve its 
bioavailability and reduce its side effects which are caused 
when given conventionally. Initial pre-formulation studies 
using FTIR spectroscopy reveals that there are no 
interactions between Albendazole and other excipients and 
hence they can be used for the preparation of nanoparticles. 
Albendazole nanoparticles were prepared by hot 
homogenization method under high magnetic stirring using 
stearic acid as lipid and poloxamer 188 was used as 
surfactant. On whole 8 batches of formulations were 
prepared by varying the amount of lipid and surfactant and 
were evaluated for various parameters like particle size, 
shape, morphology, physical state, entrapment efficiency, 
Drug content and in vitro drug release. Particle size was 
measured using Malvern Zeta sizer and the size range of the 
particles was found to be in the range of 110.6 ±1.5 nm to 
400.9 ± 2.4nm. Increase in size of nanoparticles was 
observed when we gradually increase the lipid content. The 
different concentrations of surfactant were evaluated for 
optimum one required for the preparation of stabilized solid 
lipid nanoparticles.  The entrapment efficiencies varied from 
a minimum of 43.56 ± 0.95 % to a maximum of 85.1 ±0.58% 
and it can be concluded that higher amount of lipid is 
necessary for obtaining a good entrapment efficiency. The 
drug content of albendazole nanoparticles for all formulation 
ranges from 65.8% to 98.1%.  Albendazole, being a 
hydrophobic drug has moderate entrapment efficiency. A 
spherical shape was observed for the particles and the 
particles had a smooth morphology when examined under 
SEM. In vitro release studies of the formulations carried out 
in pH 7.4 PBS showed that the total amount of drug is 
released for 9hrs with sustained effect. Taking the particle 
size, entrapment efficiency and in vitro release into account 
F4 was found out to be the best formulation which has a 
particle size of 249 ± 0.59 nm and entrapment efficiency of 
85.1 ±0.58%. The drug content was release from 98.1%. 
Further, F4 is one among the few formulations which 
showed a drug release up to 9hrs, perform with release 
order kinetics like zero order, first order, Higuchi matrix, 
korsmeyer peppas it must best fit the model was zero order 
kinetics. The stability studies are performed with 
appearance of the formulation will stored at room 
temperature, the formulations showed instability by 
formation of larger floccules and when dispersed in water 
the solution turned into heavier particles. Whereas, the 
formulation when stored in refrigerated condition was stable 
with no visible floccules formation. The particle size of the 
formulation is evaluated by photon correlation spectroscopy 
and the particle size. That the formulations showed a drastic 
increase in size when stored at room temperature where the 
size of particles increased from an initial to 343.7 ±7.9 nm at 
the end of 1 month to 898.1 ± 5.8 nm at the end of 2 months. 
Entrapment efficiency of the formulation was determined at 
each interval to ensure that the drug molecules didn’t 
undergo any degradation during storage. 
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